Adjuvant radiation field extent and sites of failure in node positive endometrioid endometrial cancer Journal Article


Authors: Yerramilli, D.; Chen, Y. H.; Venkatachalam, V.; Alban, G. M.; Buscariollo, D. L.; Cheng, T.; King, M. T.; Pretz, J. L.; Russo, A. L.; Lee, L. J.
Article Title: Adjuvant radiation field extent and sites of failure in node positive endometrioid endometrial cancer
Abstract: Purpose: In patients with node-positive endometrial cancer, adjuvant radiation therapy with chemotherapy decreases local-regional recurrence compared with chemotherapy alone. However, the optimal radiation field borders and extent of nodal coverage have not been well studied. In a multi-institutional cohort, survival outcomes and sites of failure were analyzed for patients with International Federation of Gynaecology and Obstetrics (FIGO) stage IIIC endometrioid endometrial cancer treated with pelvic radiation therapy (PRT) versus extended-field radiation therapy (EFRT), which encompassed high para-aortic lymph nodes. Methods and Materials: In a multi-institutional retrospective study, 143 patients with FIGO stage IIIC1 or IIIC2 endometrioid endometrial cancer treated with adjuvant radiation therapy from 2000 to 2016 were identified. Patient subgroups were classified by substage and radiation field extent: stage IIIC1 received EFRT, stage IIIC1 received PRT, and stage IIIC2 received EFRT. Recurrence-free survival (RFS), overall survival (OS), and out-of-field recurrence were calculated by the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards model. Sites of failure were categorized as within or outside the radiation field. Results: The median follow-up was 59 months; 87% of patients received chemotherapy. The 5-year RFS and OS rates were 73% and 87%, respectively. By subgroup, 5-year RFS rates were 79% for stage IIIC1 EFRT, 73% for stage IIIC1 PRT, and 69% for stage IIIC2 EFRT (P = .4). On multivariate analysis, the recurrence risk was highest for stage IIIC2 EFRT, although this result was not statistically significant (adjusted hazard ratio, 2.0; P = .4). In-field vaginal and nodal recurrences were observed in 2 patients (1%) and 4 patients (3%), respectively. Of 78 patients with stage IIIC1 cancer treated with PRT, 5 (6%) had isolated para-aortic nodal relapse outside the radiation field; 3 were long-term survivors (more than 6 years after salvage therapy). For patients with para-aortic recurrence, 86% had lymphovascular invasion, 71% had myometrial invasion of ≥50%, and 57% had grade 3 disease. Conclusions: Adjuvant chemoradiation therapy resulted in excellent survival outcomes for patients with FIGO stage IIIC endometrioid endometrial cancer. For patients with positive pelvic nodes, isolated para-aortic relapse outside the PRT field was uncommon and amenable to salvage therapy. © 2021 American Society for Radiation Oncology
Journal Title: Practical Radiation Oncology
Volume: 11
Issue: 5
ISSN: 1879-8519
Publisher: Elsevier Inc.  
Date Published: 2021-09-01
Start Page: 394
End Page: 403
Language: English
DOI: 10.1016/j.prro.2021.04.006
PUBMED: 34015544
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 October 2021 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors